AdaptHealth Corp. (AHCO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers AdaptHealth Corp.'s unaudited quarterly results for the period ended June 30, 2024. AdaptHealth is a national provider of home medical equipment (HME), medical supplies, and related services, serving approximately 4.2 million patients annually across 50 states. The company operates as a single reporting segment. During the quarter, the company completed a leadership transition, with Suzanne Foster assuming the role of Chief Executive Officer effective May 20, 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD Q2 2024 | YTD Q2 2023 |
|---|---|---|---|---|
| Net Revenue | $805,975 | $793,286 | $1,598,472 | $1,537,912 |
| Operating Income | $52,047 | $54,262 | $102,578 | $80,439 |
| Net Income (Attributable to AHCO) | $19,435 | $13,977 | $17,301 | $29,684 |
| Diluted EPS | $0.13 | $0.09 | $0.12 | $0.03 |
| Adjusted EBITDA | $165,315 | $171,045 | $323,800 | $305,009 |
| Free Cash Flow | $116,712 | $3,709 | $77,856 | $54,837 |
| Cash and Equivalents | $69,832 | $45,126 | $69,832 | $45,126 |
| Total Debt (Gross) | $2,100,000 | $2,170,000 | $2,100,000 | $2,170,000 |
Note: Debt figures represent the sum of the Secured Term Loan ($650M) and Senior Unsecured Notes ($1.45B). Adjusted EBITDA and Free Cash Flow are non-GAAP measures.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 1.6% quarter-over-quarter and 3.9% year-over-year (YTD). Growth was driven by non-acquired growth in Sleep (+6.5%) and Respiratory (+4.6%) segments, partially offset by a 10.5% decline in the Diabetes segment due to payer shifts toward pharmacy channels.
- Profitability: Operating income decreased slightly in Q2 ($52.0M vs $54.3M) due to a $6.5M goodwill impairment charge related to an immaterial business disposal. However, YTD operating income increased 27.5% to $102.6M.
- Net Income: Q2 net income attributable to AdaptHealth increased 39.0% to $19.4M, driven by a non-cash gain of $7.0M from the change in fair value of warrant liability. YTD net income decreased 41.7% to $17.3M, primarily due to a $22.7M non-cash gain in the prior year period from warrant liability changes that did not recur.
- Cash Flow: Free cash flow improved significantly to $116.7M in Q2 (vs $3.7M in Q2 2023), aided by the resolution of claims processing delays from the Change Healthcare cybersecurity incident and participation in the Optum Temporary Funding Assistance Program.
Guidance, Outlook, Risks, and Unusual Items
- Goodwill Impairment: The company recorded a $13.1M non-cash goodwill impairment charge YTD related to the disposition of certain custom rehab technology assets. Management does not anticipate further impairments based on current assessments.
- Litigation Settlements: The company settled a securities class action lawsuit. The settlement included $17.8M in cash from the company, $32.2M from insurance, and 1 million shares of common stock. A derivative action was also settled for $0.9M in legal fees. These resulted in non-recurring expenses and fair value adjustments in the current period.
- Cybersecurity Impact: The Change Healthcare data breach in early 2024 delayed claims processing and cash collections. By June 30, 2024, pending claims were processed, and receivables were substantially collected. The company received $39.6M in temporary funding assistance, due for repayment by December 31, 2024.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in internal control over financial reporting. These weaknesses relate to revenue transaction processing via third-party providers, procurement controls, and inventory valuation. Remediation efforts are ongoing.
- Debt Covenants: The company remains in compliance with its credit agreement covenants. As of June 30, 2024, it had approximately $346.4M of borrowing capacity available under its revolving credit facility.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation plans for the identified material weaknesses in revenue processing and inventory controls, as these pose ongoing risks to financial reporting accuracy.
- Diabetes Segment Trends: Monitor the trajectory of the Diabetes segment, which continues to face headwinds from payer shifts to pharmacy channels and manufacturer vertical integration.
- Debt Service Capacity: Assess the impact of high interest rates on the $2.1B debt load, particularly the variable rate term loan, and the company's ability to maintain leverage ratios under its credit agreement.
- Legal Exposure: Track the status of the ongoing False Claims Act investigation regarding ventilator billing and the Allegheny County class action lawsuit regarding diabetes billing practices.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBITDA and Free Cash Flow to ensure understanding of the significant non-cash adjustments (warrant liability, goodwill impairment) included in the metrics.